RT期刊文章SR电子T1趋化因子的作用，他们的基因多态性在可重型NSCLC JF欧洲呼吸期刊Jo EUR Respir J FD欧洲呼吸学会SP 4094 Do 10.1183 / 13993003.Conground-2020.4094 VO 56是SUP 64 A1Dröslerová，MarieA188bet官网地址1ŠetlováMartina A1Vašáková，Martina A1Tašková，Alice A1 Hytych，Vladislav A1Richterová，Eva A1Matžjčková，Milada yr 2020 ul //www.qdcxjkg.com/content/56/suppl_64/4094.abstract ab目标：趋化因子是一部分靶向肿瘤的免疫反应。趋化因子表达受基因多态性的影响。他们的角色在可重定型的NSCLC.aim中尚不清楚：将可重置的NSCLC患者的血浆中的趋化因素浓度（CCL2，CCL8，CXCL12）与没有癌症的人进行比较。要了解趋化因子浓度是否根据疾病的阶段而异。评估基因多态性CCL2 RS3760396，CCL8 RS3138035，CXCL12 RS1804429。为了了解基因多态性是否在NSCLC患者和没有癌症的那些之间的不同。他们经历了标准的诊断和分期过程。我们诊断出42例NSCLC患者，27名患者患有良性肺病理（对照组）。 We assessed chemokine concentrations in peripheral blood by ELISA LSBio Kits. We assessed gene polymorphisms by quantitative real- time polymerase chain reaction with TaqMan hydrolysis probes. Parametric statistics was used for analysis.Results: There was no difference in concentrations of chemokines in plasma of NSCLC patients and control group. The CXCL12 concentrations positively corelated with the tumor extent expressed by clinical stage (mean values: stage I 5.08ng/ml; SEM 0.59; stage II and IIIA 7.82ng/ml; SEM 1.06; p= 0.022). There was no difference in gene polymorphisms between NSCLC patients and control group (CCL2 rs3760396 p= 0.160; CCL8 rs3138035 p= 0.589; CXCL12 rs1804429 p= 0.233).Conclusion: The CXCL12 relates tumor growth and might be a biomarker of advanced disease. We might need to include more patients to find out more about gene polymorphisms.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4094.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).